The immune checkpoint with the lowest expression in breast cancer was VISTA, where increased expression was observed in only 25% of Luminal A tumors, 20% in Luminal B, 6.7% in Her-2+, and 40% in the triple-negative. This evidence concerns the gene ERBB2 and breast carcinoma.